METiS Pharmaceutical will present two preclinical studies on mRNA cancer immunotherapy in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2025, to be held in Chicago, USA, from April 25 to 30, 2025 (local time).
Conference Name: AACR Annual Meeting 2025
Conference Date: April 25–30, 2025
Conference Venue: McCormick Place Convention Center, Chicago, Illinois, USA
Abstract Number: 4409
Abstract Title: Preclinical development of an mRNA-encoded T cell engager targeting Glypican-3 with tissue- and tumor-specific enrichment in hepatocellular carcinoma
Session Track: T Cell Engagers
Presentation Time: April 28, 14:00–17:00 (local time)
Poster Section: 38
Poster Board Number: 10
Presentation Number: 3502
Abstract Number: 4379
Abstract Title: mRNA-encoded HPV16/18 therapeutic vaccine with co-stimulator to activate antigen presenting cells and promote T cell-mediated anti-tumor activity
Session Track: Virology and Cancer
Presentation Time: April 27, 14:00–17:00 (local time)
Poster Section: 39
Poster Board Number: 6
Presentation Number: 937
About AACR 2025
The 116th Annual Meeting of the American Association for Cancer Research (AACR) will be held from April 25 to 30, 2025, at McCormick Place Convention Center in Chicago, Illinois, USA. As the premier global event in cancer research, the AACR Annual Meeting brings together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates from around the world to share and discuss the latest breakthroughs in cancer science and medicine.
